Andersen, Tor Kristian
Huszthy, Peter C.
Gopalakrishnan, Ramakrishna P.
Jacobsen, Johanne T.
Fauskanger, Marte
Tveita, Anders A.
Grødeland, Gunnveig
Bogen, Bjarne
Funding for this research was provided by:
KG Jebsen Foundation
Article History
Received: 30 July 2018
Accepted: 9 January 2019
First Online: 11 February 2019
Competing interests
: B.B. and G.G. are inventors on (1) patents (B.B.) and (2) patent applications (G.G., B.B.) on the described vaccine molecules, filed by the TTO office of the University of Oslo and Oslo University Hospital, according to institutional rules. (1) Patent applicant: Inven2/Vaccibody AS. Inventors: Bjarne Bogen, Agnete B. Fredriksen, Inger Sandlie. Application number: European patent No. 1599504. Status of Application: granted in EU and the US. Specific aspect of manuscript covered in patent Application: Homodimeric modular constructs targeting antigens to antigen presenting cells. (2) Patent applicant: Inven2. Inventors: Bjarne Bogen, Gunnveig Grødeland, Agnete B. Fredriksen. Application number: WO2017/221072. Status of Application: National Phase from Dec 20, 2018. Specific aspect of manuscript covered in patent Application: A human version of the MHCII-specific targeting moiety. BB is head of the Scientific panel of Vaccibody AS, and holds shares in the company.